MPH-T NR today 79m at 1.94
Medicure to present Matched study results at ASH 2006
2006-04-10 10:06 ET - News Release
Mr. Derek Reimer reports
MEDICURE TO PRESENT MATCHED RESULTS AT THE 21ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HYPERTENSION
Medicure Inc.'s two posters outlining the positive results of the phase II Matched study with MC-4232 have been accepted for presentation at the American Society of Hypertension (ASH) annual scientific meeting and exposition being held in New York at the New York Hilton Hotel from May 16, 2006, to May 20, 2006. ASH is the largest U.S. organization dedicated exclusively to hypertension and related cardiovascular disease.
"We look forward to presenting the Matched clinical results at this important scientific forum," stated Dr. Lacourciere, MD, FRCP, FACP, principal investigator of the Matched study. "The opportunity to present the results validates the importance of the study's findings and the expanding need for new approaches to treat patients with diabetes and hypertension."
"This is an ideal setting for our first formal presentation of the Matched clinical results," commented Medicure's president and chief executive officer, Albert D. Friesen, PhD. "Patients with co-existing diabetes and hypertension, like those studied in Matched, are extremely difficult to treat and frequently require multiple drugs to control their cardiovascular and metabolic risk factors. MC-4232, as demonstrated in Matched, is currently one of the only drugs in development that addresses both cardiovascular and metabolic risk factors in this difficult to treat patient population."
Dr. Lacourciere, director of the hypertension research unit, Centre Hospitalier de l'Universite Laval Sainte-Foy in Quebec, will present the two posters describing the anti-hypertensive and metabolic effects of MC-4232. The abstract, which is titled evaluation of the anti-hypertensive effects of MC-1 alone and in combination with lisinopril on ambulatory BP in hypertensive patients with Type 2 diabetes mellitus, will be presented at 8:30 a.m. Eastern Time on May 17, 2006. The second abstract, which is titled the combination of MC-1 and lisinopril has beneficial effects on carbohydrate and lipid metabolism in hypertensives with Type 2 diabetes mellitus, will be presented at 4 p.m. Eastern Time on May 16, 2006.
Medicure completed the phase II Matched study (MC-1 and ACE therapeutic combination for hypertensive diabetics) in September, 2005. The study results demonstrated that MC-4232 had a statistically significant reduction in both primary blood pressure and metabolic end points.
We seek Safe Harbor.
